相关实验视频
Updated: Jun 29, 2026

12:08
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
双子座表面活性剂具有二糖间隔剂
1Department of Chemistry, Emory University, Atlanta, Georgia 30322, USA.
Journal of the American Chemical Society
|July 18, 2001
概括
合成了两种新家族的双子表面活性剂与三糖间隔剂. 系列A双胞胎形成不溶性结构,而系列B双胞胎形成溶性,通过分子建模解释.
科学领域:
- 合体和表面化学
- 超分子化学 超分子化学
- 材料科学 材料科学 材料科学
背景情况:
- 双子座的表面活性剂,其特点是有两个水友头组和两个由间隔器连接的疏水尾,引起了大量的兴趣.
- 三糖是一种非减小型二糖体,为两设计提供独特的结构和功能性质.
研究的目的:
- 合成和描述两种新的双子座表面活性剂家族,利用三糖作为极地间隔剂.
- 调查结构修改 (非离子与离子) 对这些双子表面活性剂的自我组装行为和物理化学性质的影响.
主要方法:
- 合成非离子 (A 系列) 和阴离子 (B 系列) 双子表面活性剂与三糖.
- 使用热度计,张力计,导电量测量,显微镜,表面平衡研究和光散射进行表征.
- 使用珀力场进行分子建模,以阐明结构与属性关系.
主要成果:
- 系列A双胞胎,尽管有水友群,但表现出水不溶性,形成囊泡和管状结构,模仿脂.
- 系列B双子体表现出水溶性,形成微粒,临界微粒度明显低于常规表面活性剂.
- 分子建模表明A系列的管状形状有利于双层包装,B系列的形状有利于菌形成.
结论:
- 头组的性质 (胺基与四级) 极大地决定了基于三醇的双子表面活性剂的自我组装行为和可溶性.
- 树脂素可以作为一个实质性的头部组,影响包装参数和总体形态.
- 多种实验和计算方法之间的一致性对于全面了解复杂的表面活性剂系统至关重要.
相关概念视频
Sugars as Energy Storage Molecules
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
Surface Active Agents
Surfactants, named for their behavior at interfaces, positively adsorb at the interfaces of two phases, reducing interfacial tension. Their versatility as emulsifiers, detergents, and foaming agents stems from this ability. Surfactants, often termed amphiphiles, share the property of amphipathy, with molecules having both hydrophilic and hydrophobic portions. The hydrophilic part is called the head, and the hydrophobic part, including an elongated alkyl substituent, forms the tail.Surfactants...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

